問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Veterans General Hosptial (在職)

Division of Infectious Disease

Division of General Internal Medicine

China Medical University Hospital (在職)

Division of Infectious Disease

更新時間：2023-09-19

李欣蓉Lee, Susan Shin-Jung
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -3 個月

  • whei2chen@gmail.com

Recruiting Trial

11Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李欣蓉

List

32Cases

2024-12-01 - 2025-11-04

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2025-01-01 - 2031-01-26

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2031-01-26

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2031-01-26

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-07-01 - 2033-11-30

Phase III

Not yet recruiting
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

  • Condition/Disease

    HIV Infections

  • Test Drug

    膜衣錠 注射劑 靜脈輸注液 靜脈輸注液

Participate Sites
5Sites

Not yet recruiting1Sites

2025-03-31 - 2028-06-30

Active
A retrospective, observational post-marketing study evaluating the efficacy and safety of intravenously administered polymyxin B and colistin methanesulfonate in treating patients with carbapenem-resistant, Gram-negative bacterial infections.

  • Condition/Disease

    1. Clinical response rate of the polymyxin B group assessed by infection site and infectious pathogen at TOC (End of Treatment (EOT) + 7 days). 2. Clinical response rate of the two treatment groups at TOC. 3. Microbiological response rate of the polymyxin B group assessed by infection site and infectious pathogen at TOC. 4. Microbiological response rate of the two treatment groups at TOC. 5. All-cause mortality rate of the two treatment groups at day 28. 6. Infection-related mortality rate of the two treatment groups at day 28.

  • Test Drug

    POLYMYXIN B SULFATE

Participate Sites
13Sites

Recruiting13Sites

2018-08-01 - 2023-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2018-05-01 - 2023-05-17

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

2022-12-15 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2025-11-25 - 2027-04-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB